FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313379569> ?p ?o ?g. }

• W4313379569 endingPage "103296" @default.
• W4313379569 startingPage "103296" @default.
• W4313379569 abstract "Metachromatic leukodystrophy (MLD) is a lysosomal enzyme deficiency disorder leading to demyelination and subsequently to a progressive decline in cognitive and motor function. It affects mainly white matter where changes during the course of the disease can be visualized on T2-weighted MRI as hyperintense areas. Associated changes in brain metabolism can be quantified by MR spectroscopy (MRS) and may give complementary information as biomarkers for disease characterisation and progression. Our study aimed to further investigate the correlation of MRS with clinical parameters for motor and cognitive function by using a model free MRS analysis approach that would be precise and straightforward to implement. 53 MRS datasets derived from 29 patients (10 late-infantile, 19 juvenile) and 12 controls were acquired using a semi-LASER CSI sequence covering a slice through the centrum semiovale above the corpus callosum. We defined four regions of interest in the white matter (frontal white matter [FWM] and the cortico-spinal tract [CST] area, each left and right) and one in cortical grey matter. Spectra were analysed using a model and fitting free approach by calculating the definite integral of 10 intervals which were distributed along the whole spectrum. These 10 intervals were orientated towards the main peaks of the metabolites N-acetylaspartate (NAA), creatine, myo-inositol, choline, glutamine/glutamate and aspartate to approximately attribute changes in the intervals to corresponding metabolites. Their ratios to the main creatine peak integral were correlated with clinical parameters assessing motor and cognitive abilities. Furthermore, in a post-hoc analysis, NAA levels of a subset of 21 MR datasets were correlated to NAA levels in urine measured by 1H (proton) nuclear magnetic resonance (NMR) spectroscopy. The applied interval integration method was validated in the control cohort against the standard approach, using spectral profile templates of known metabolites (LCModel). Both methods showed good agreement, with coefficients of variance being slightly lower for our approach compared to the related LCModel results. Moreover, the new approach was able to extract information out of the frequency range around the main peaks of aspartate and glutamine where LCModel showed only few usable values for the respective metabolites. MLD spectra clearly differed from controls. The most pronounced differences were found in white matter (much less in grey matter), with larger values corresponding to main peaks of myo-inositol, choline and aspartate, and smaller values associated with NAA and glutamine. Late-infantile patients had more severe changes compared to later-onset patients, especially in intervals corresponding to NAA, aspartate, myo-inositol, choline and glutamine. There was a high correlation of several intervals in the corticospinal tract region with motor function (with the most relevant interval corresponding to NAA peak with a correlation coefficient of −0.75; p < 0.001), while cognitive function, by means of IQ, was found to be most correlating in frontal white matter corresponding to the NAA peak (r = 0.84, p < 0.001). The post-hoc analysis showed that the main NAA peak interval correlated negatively with the NAA in urine (r = −0.584, p < 0.001). The applied model and fitting free interval integration approach to analyse MRS data of a semi-LASER sequence at 3T suits well to detect and quantify pathological changes in MLD patients through the different courses of the disease and correlates well with clinical symptoms while showing smaller dimensions of variation compared to the more sophisticated single metabolite analysis using LCModel. NAA seems the most clinically meaningful biomarker to use in this context. Its correlation with urine measurements further underlines its potential as a clinically and biologically useful parameter of disease progression in MLD." @default.
• W4313379569 created "2023-01-06" @default.
• W4313379569 creator A5028109673 @default.
• W4313379569 creator A5036648868 @default.
• W4313379569 creator A5048032356 @default.
• W4313379569 creator A5051884303 @default.
• W4313379569 creator A5056602566 @default.
• W4313379569 creator A5063857357 @default.
• W4313379569 creator A5068418202 @default.
• W4313379569 creator A5068451355 @default.
• W4313379569 creator A5069329426 @default.
• W4313379569 date "2023-01-01" @default.
• W4313379569 modified "2023-09-26" @default.
• W4313379569 title "MR-spectroscopy in metachromatic leukodystrophy: A model free approach and clinical correlation" @default.
• W4313379569 cites W1504726351 @default.
• W4313379569 cites W1886883567 @default.
• W4313379569 cites W1970020548 @default.
• W4313379569 cites W1981614146 @default.
• W4313379569 cites W2005030722 @default.
• W4313379569 cites W2013371492 @default.
• W4313379569 cites W2023836538 @default.
• W4313379569 cites W2042912916 @default.
• W4313379569 cites W2051607590 @default.
• W4313379569 cites W2053623186 @default.
• W4313379569 cites W2056029923 @default.
• W4313379569 cites W2099292814 @default.
• W4313379569 cites W2102118295 @default.
• W4313379569 cites W2110147954 @default.
• W4313379569 cites W2123526955 @default.
• W4313379569 cites W2137184120 @default.
• W4313379569 cites W2166995213 @default.
• W4313379569 cites W2409466680 @default.
• W4313379569 cites W2470546931 @default.
• W4313379569 cites W2558110624 @default.
• W4313379569 cites W2615618829 @default.
• W4313379569 cites W2753361113 @default.
• W4313379569 cites W2754546465 @default.
• W4313379569 cites W2785776071 @default.
• W4313379569 cites W2932841619 @default.
• W4313379569 cites W3008758753 @default.
• W4313379569 cites W3091899305 @default.
• W4313379569 cites W3110798427 @default.
• W4313379569 cites W3156506134 @default.
• W4313379569 cites W3159995035 @default.
• W4313379569 cites W3194341048 @default.
• W4313379569 cites W4206611033 @default.
• W4313379569 cites W4210736615 @default.
• W4313379569 doi "https://doi.org/10.1016/j.nicl.2022.103296" @default.
• W4313379569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36563646" @default.
• W4313379569 hasPublicationYear "2023" @default.
• W4313379569 type Work @default.
• W4313379569 citedByCount "1" @default.
• W4313379569 countsByYear W43133795692023 @default.
• W4313379569 crossrefType "journal-article" @default.
• W4313379569 hasAuthorship W4313379569A5028109673 @default.
• W4313379569 hasAuthorship W4313379569A5036648868 @default.
• W4313379569 hasAuthorship W4313379569A5048032356 @default.
• W4313379569 hasAuthorship W4313379569A5051884303 @default.
• W4313379569 hasAuthorship W4313379569A5056602566 @default.
• W4313379569 hasAuthorship W4313379569A5063857357 @default.
• W4313379569 hasAuthorship W4313379569A5068418202 @default.
• W4313379569 hasAuthorship W4313379569A5068451355 @default.
• W4313379569 hasAuthorship W4313379569A5069329426 @default.
• W4313379569 hasBestOaLocation W43133795691 @default.
• W4313379569 hasConcept C103191249 @default.
• W4313379569 hasConcept C126322002 @default.
• W4313379569 hasConcept C126838900 @default.
• W4313379569 hasConcept C142724271 @default.
• W4313379569 hasConcept C143409427 @default.
• W4313379569 hasConcept C15744967 @default.
• W4313379569 hasConcept C169760540 @default.
• W4313379569 hasConcept C185592680 @default.
• W4313379569 hasConcept C2776100374 @default.
• W4313379569 hasConcept C2776326100 @default.
• W4313379569 hasConcept C2778183499 @default.
• W4313379569 hasConcept C2779134260 @default.
• W4313379569 hasConcept C2779247111 @default.
• W4313379569 hasConcept C2779349466 @default.
• W4313379569 hasConcept C2779896295 @default.
• W4313379569 hasConcept C2781123555 @default.
• W4313379569 hasConcept C2781192897 @default.
• W4313379569 hasConcept C2989005 @default.
• W4313379569 hasConcept C515207424 @default.
• W4313379569 hasConcept C55493867 @default.
• W4313379569 hasConcept C71924100 @default.
• W4313379569 hasConceptScore W4313379569C103191249 @default.
• W4313379569 hasConceptScore W4313379569C126322002 @default.
• W4313379569 hasConceptScore W4313379569C126838900 @default.
• W4313379569 hasConceptScore W4313379569C142724271 @default.
• W4313379569 hasConceptScore W4313379569C143409427 @default.
• W4313379569 hasConceptScore W4313379569C15744967 @default.
• W4313379569 hasConceptScore W4313379569C169760540 @default.
• W4313379569 hasConceptScore W4313379569C185592680 @default.
• W4313379569 hasConceptScore W4313379569C2776100374 @default.
• W4313379569 hasConceptScore W4313379569C2776326100 @default.
• W4313379569 hasConceptScore W4313379569C2778183499 @default.
• W4313379569 hasConceptScore W4313379569C2779134260 @default.
• W4313379569 hasConceptScore W4313379569C2779247111 @default.

• next